Tyrosine Kinase Inhibitor Therapy for Brain Metastases in Non-Small-Cell Lung Cancer: A Primer for Radiologists

References

1. 1.↵
   1. Baik CS,
   2. Chamberlain MC,
   3. Chow LQ

   . Targeted therapy for brain metastases in EGFR-mutated and ALK-rearranged non-small-cell lung cancer. J Thorac Oncol 2015;10:1268–78 doi:10.1097/JTO.0000000000000615 pmid:26107553

   CrossRefPubMed
2. 2.↵
   1. Hall WA,
   2. Djalilian HR,
   3. Nussbaum ES, et al

   . Long-term survival with metastatic cancer to the brain. Med Oncol 2000;17:279–86 doi:10.1007/bf02782192 pmid:11114706

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Proto C,
   2. Imbimbo M,
   3. Gallucci R, et al

   . Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future. Transl Lung Cancer Res 2016;5:563–78 doi:10.21037/tlcr.2016.10.16 pmid:28149752

   CrossRefPubMed
4. 4.↵
   1. Mehta MP,
   2. Rodrigus P,
   3. Terhaard CHJ, et al

   . Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003;21:2529–36 doi:10.1200/JCO.2003.12.122 pmid:12829672

   Abstract/FREE Full Text
5. 5.↵
   1. Franciosi V,
   2. Cocconi G,
   3. Michiara M, et al

   . Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999;85:1599–1605 pmid:10193952

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Petrelli F,
   2. Ghidini M,
   3. Lonati V, et al

   . The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: a systematic review and pooled analysis. Eur J Cancer 2017;84:141–48 doi:10.1016/j.ejca.2017.07.024 pmid:28810186

   CrossRefPubMed
7. 7.↵
   1. Verma J,
   2. Jonasch E,
   3. Allen P, et al

   . Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. Cancer 2011;117:4958–65 doi:10.1002/cncr.26138 pmid:21484781

   CrossRefPubMed
8. 8.↵
   1. Kerr KM,
   2. López-Ríos F

   . Precision medicine in NSCLC and pathology: how does ALK fit in the pathway? Ann. Oncol 2016;27:ii16–24 doi:10.1093/annonc/mdw302 pmid:27573752

   CrossRefPubMed
9. 9.↵
   1. Lindeman NI,
   2. Cagle PT,
   3. Aisner DL, et al

   . Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors. Arch Pathol Lab Med 2018;142:321–46 doi:10.5858/arpa.2017-0388-CP pmid:29355391

   CrossRefPubMed
10. 10.↵
    1. Narita Y,
    2. Matsushima Y,
    3. Shiroiwa T, et al

    . Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer. Lung Cancer 2015;90:71–77 doi:10.1016/j.lungcan.2015.07.006 pmid:26259876

    CrossRefPubMed
11. 11.↵
    1. Holleman MS,
    2. Al MJ,
    3. Zaim R, et al

    . Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations. Eur J Health Econ 2019 Sep 20. [Epub ahead of print] doi:10.1007/s10198-019-01117-3 pmid:31541309

    CrossRefPubMed
12. 12.↵
    1. Djalalov S,
    2. Beca J,
    3. Hoch JS, et al

    . Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. J Clin Oncol 2014;32:1012–19 doi:10.1200/JCO.2013.53.1186 pmid:24567430

    Abstract/FREE Full Text
13. 13.↵
    1. Carlson JJ,
    2. Kangho S,
    3. Orfanos P, et al

    . Cost effectiveness of alectinib vs. crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Pharmacoeconomics 2018;36:495–504 doi:10.1007/s40273-018-0625-6 pmid:29488070

    CrossRefPubMed
14. 14.↵
    1. Glitza Oliva IC,
    2. Schvartsman G,
    3. Tawbi H

    . Advances in the systemic treatment of melanoma brain metastases. Ann Oncol 2018;29:1509–20 doi:10.1093/annonc/mdy185 pmid:29790899

    CrossRefPubMed
15. 15.↵
    1. Svokos KA,
    2. Salhia B,
    3. Toms SA

    . Molecular biology of brain metastasis. Int J Mol Sci 2014;15:9519–30 doi:10.3390/ijms15069519 pmid:24879524

    CrossRefPubMed
16. 16.↵
    1. Löscher W,
    2. Potschka H

    . Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005;2:86–98 doi:10.1602/neurorx.2.1.86 pmid:15717060

    Abstract/FREE Full Text
17. 17.↵
    1. Connell JJ,
    2. Chatain G,
    3. Cornelissen B, et al

    . Selective permeabilization of the blood-brain barrier at sites of metastasis. J Natl Cancer Inst 2013;105:1634–43 doi:10.1093/jnci/djt276 pmid:24108809

    CrossRefPubMed
18. 18.↵
    1. Tan J,
    2. Li M,
    3. Zhong W, et al

    . Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: a direct comparative analysis of icotinib, gefitinib, and erlotinib in a nude mouse model. Oncotarget 2017;8:98771–81 doi:10.18632/oncotarget.21936 pmid:29228726

    CrossRefPubMed
19. 19.↵
    1. García-Román J,
    2. Zentella-Dehesa A

    . Vascular permeability changes involved in tumor metastasis. Cancer Lett 2013;335:259–69 doi:10.1016/j.canlet.2013.03.005 pmid:23499893

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Wang BX,
    2. Ou W,
    3. Mao XY, et al

    . Impacts of EGFR mutation and EGFR-TKIs on incidence of brain metastases in advanced non-squamous NSCLC. Clin Neurol Neurosurg 2017;160:96–100 doi:10.1016/j.clineuro.2017.06.022 pmid:28704781

    CrossRefPubMed
21. 21.↵
    1. O'Kane GM,
    2. Leighl NB

    . Systemic therapy of lung cancer CNS metastases using molecularly targeted agents and immune checkpoint inhibitors. CNS Drugs 2018;32:527–42 doi:10.1007/s40263-018-0526-4 pmid:29799091

    CrossRefPubMed
22. 22.↵
    1. Abdallah SM,
    2. Wong A

    . Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options? Curr Oncol 2018;25:S103–14 doi:10.3747/co.25.3733 pmid:29910653

    CrossRefPubMed
23. 23.↵
    1. Park SJ,
    2. Kim HT,
    3. Lee DH, et al

    . Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer 2012;77:556–60 doi:10.1016/j.lungcan.2012.05.092 pmid:22677429

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Maemondo M,
    2. Inoue A,
    3. Kobayashi K, et al

    ; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380–88 doi:10.1056/NEJMoa0909530 pmid:20573926

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Pao W,
    2. Balak MN,
    3. Riely GJ, et al

    . Molecular analysis of NSCLC patients with acquired resistance to gefitinib or erlotinib. J Clin Oncol 2006;24:7078 doi:10.1200/jco.2006.24.18_suppl.7078

    CrossRef
26. 26.↵
    1. Hoffknecht P,
    2. Tufman A,
    3. Wehler T, et al

    ; Afatinib Compassionate Use Consortium (ACUC). Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol 2015;10:156–63 doi:10.1097/JTO.0000000000000380 pmid:25247337

    CrossRefPubMed
27. 27.↵
    1. Yu HA,
    2. Arcila ME,
    3. Rekhtman N, et al

    . Analysis of tumor specimens at the time of acquired resistance to EGFR TKI therapy in 155 patients with EGFR mutant lung cancers. Clin Cancer Res 2013;19:2240–47 doi:10.1158/1078-0432.CCR-12-2246 pmid:23470965

    Abstract/FREE Full Text
28. 28.↵
    1. Griffin R,
    2. Ramirez RA

    . Molecular targets in non–small cell lung cancer. Ochsner J 2017;17:388–92 pmid:29230123

    Abstract/FREE Full Text
29. 29.↵
    1. Malapelle U,
    2. Ricciuti B,
    3. Baglivo S, et al

    . Osimertinib. Recent Results Cancer Res 2018;211:257–76 doi:10.1007/978-3-319-91442-8_18 pmid:30069773

    CrossRefPubMed
30. 30.↵
    1. Tan CS,
    2. Kumarakulasinghe NB,
    3. Huang YQ, et al

    . Third generation EGFR TKIs: current data and future directions. Mol Cancer 2018;17:1–14 doi:10.1186/s12943-018-0778-0 pmid:29455654

    CrossRefPubMed
31. 31.↵
    1. Reungwetwattana T,
    2. Nakagawa K,
    3. Cho BC, et al

    . CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non–small-cell lung cancer. J Clini Oncol 2018 Aug 28. [Epub ahead of print] doi:10.1200/JCO.2018.78.3118 pmid:30153097

    CrossRefPubMed
32. 32.↵
    1. Soria JC,
    2. Ohe Y,
    3. Vansteenkiste J, et al

    ; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018;378:113–25 doi:10.1056/NEJMoa1713137 pmid:29151359

    CrossRefPubMed
33. 33.↵
    1. Costa DB,
    2. Shaw AT,
    3. Ou SH, et al

    . Clinical experience with crizotinib in patients with advanced ALK-rearranged non–small-cell lung cancer and brain metastases. J Clin Oncol 2015;33:1881–88 doi:10.1200/JCO.2014.59.0539 pmid:25624436

    Abstract/FREE Full Text
34. 34.↵
    1. Ricciuti B,
    2. De Giglio A,
    3. Mecca C, et al

    . Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib. Med Oncol 2018;35:1–18 doi:10.1007/s12032-018-1133-4 pmid:29666949

    CrossRefPubMed
35. 35.↵
    1. Gadgeel S,
    2. Peters S,
    3. Mok T, et al

    . Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol 2018;29:2214–22 doi:10.1093/annonc/mdy405 pmid:30215676

    CrossRefPubMed
36. 36.↵
    1. Peters S,
    2. Camidge DR,
    3. Shaw AT, et al

    ; ALEX Trial Investigators. Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer. N Engl J Med 2017;377:829–38 doi:10.1056/NEJMoa1704795 pmid:28586279

    CrossRefPubMed
37. 37.↵
    1. Crinò L,
    2. Ahn MJ,
    3. De Marinis F, et al

    . Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2. J Clin Oncol 2016;34:2866–73 doi:10.1200/JCO.2015.65.5936 pmid:27432917

    Abstract/FREE Full Text
38. 38.
    1. Camidge DR,
    2. Kim HR,
    3. Ahn MJ, et al

    . Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med 2018;379:2027–39 doi:10.1056/NEJMoa1810171 pmid:30280657

    CrossRefPubMed
39. 39.↵
    1. Shaw AT,
    2. Felip E,
    3. Bauer TM, et al

    . Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial. Lancet Oncol 2017;18:1590–99 doi:10.1016/S1470-2045(17)30680-0 pmid:29074098

    CrossRefPubMed
40. 40.↵
    1. Ou SHI,
    2. Zhu VW

    . CNS metastasis in ROS1+ NSCLC: an urgent call to action, to understand, and to overcome. Lung Cancer 2019;130:201–07 doi:10.1016/j.lungcan.2019.02.025 pmid:30885345

    CrossRefPubMed
41. 41.↵
    1. Wu YL,
    2. Yang JC,
    3. Kim DW, et al

    . Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non–small-cell lung cancer. J Clin Oncol 2018;36:1405–12 doi:10.1200/JCO.2017.75.5587 pmid:29596029

    CrossRefPubMed
42. 42.↵
    1. Ahn M,
    2. Cho BC,
    3. Siena S, et al

    . OA 14.06 entrectinib in patients with locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC). J Thorac Oncol 2017;12:S178 doi:10.1016/j.jtho.2017.09.411

    CrossRef
43. 43.↵
    1. Ou S,
    2. Shaw A,
    3. Riely G, et al

    . OA02.03 clinical activity of lorlatinib in patients with ROS1+ advanced non-small cell lung cancer: phase 2 study cohort EXP-6. J Thorac Oncol 2018;13:S322–23 doi:10.1016/j.jtho.2018.08.241

    CrossRef
44. 44.↵
    1. Lim SM,
    2. Kim HR,
    3. Lee JS, et al

    . Open-label, multicenter, phase II study of ceritinib in patients with non–small-cell lung cancer harboring ROS1 rearrangement. J Clin Oncol 2017;35:2613–18 doi:10.1200/JCO.2016.71.3701 pmid:28520527

    CrossRefPubMed
45. 45.↵
    1. Ding PN,
    2. Lord SJ,
    3. Gebski V, et al

    . Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-mutated non–small cell lung cancer. J Thorac Oncol 2017;12:633–43 doi:10.1016/j.jtho.2016.11.2236 pmid:28007626

    CrossRefPubMed
46. 46.↵
    1. Hou H,
    2. Sun D,
    3. Liu K, et al

    . The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis. Cancer Manag Res 2019;11:4109–18 doi:10.2147/CMAR.S190098 pmid:31190983

    CrossRefPubMed
47. 47.↵
    1. Del Valle MF,
    2. Chang AY

    . Real world experience on treatment, outcome and toxicity of crizotinib in patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer. J Thorac Dis 2019;11:3864–73 doi:10.21037/jtd.2019.09.15 pmid:31656659

    CrossRefPubMed
48. 48.↵
    1. Ou SH,
    2. Klempner SJ,
    3. Azada MC, et al

    . Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: implications for disease assessment and management. Lung Cancer 2015;88:355–59 doi:10.1016/j.lungcan.2015.03.022 pmid:25882777

    CrossRefPubMed
49. 49.↵
    1. Song YP,
    2. Colaco RJ

    . Radiation necrosis: a growing problem in a case of brain metastases following whole brain radiotherapy and stereotactic radiosurgery. Cureus 2018;10:e2037 doi:10.7759/cureus.2037] pmid:29541558

    CrossRefPubMed
50. 50.↵
    1. Shah RR

    . Anti-angiogenic tyrosine kinase inhibitors and reversible posterior leukoencephalopathy syndrome: could hypomagnesaemia be the trigger? Drug Saf 2017;40:373–86 doi:10.1007/s40264-017-0508-3 pmid:28181126

    CrossRefPubMed
51. 51.↵
    1. Shankar J,
    2. Banfield J

    . Posterior reversible encephalopathy syndrome: a review. Can Assoc Radiol J 2017;68:147–53 doi:10.1016/j.carj.2016.08.005 pmid:28131335

    CrossRefPubMed
52. 52.↵
    1. Yamamoto M,
    2. Serizawa T,
    3. Shuto T, et al

    . Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol 2014;15:387–95 doi:10.1016/S1470-2045(14)70061-0 pmid:24621620

    CrossRefPubMedWeb of Science
53. 53.
    1. Yamamoto M,
    2. Serizawa T,
    3. Higuchi Y, et al

    . A multi-institutional prospective observational study of stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901 study update): irradiation-related complications and long-term maintenance of Mini-Mental State Examination scores. Int J Radiat Oncol Biol Phys 2017;99:31–40 doi:10.1016/j.ijrobp.2017.04.037 pmid:28816158

    CrossRefPubMed
54. 54.↵
    1. Berghoff A,
    2. Preusser M

    . New developments in brain metastases. Ther Adv Neurol Disord 2018;11:1756286418785502 doi:10.1177/1756286418785502 pmid:30034538

    CrossRefPubMed
55. 55.↵
    1. Jindal V,
    2. Gupta S

    . Expected paradigm shift in brain metastases therapy: immune checkpoint inhibitors. Mol Neurobiol 2018;55:7072–78 doi:10.1007/s12035-018-0905-3 pmid:29383686

    CrossRefPubMed
56. 56.↵
    1. Kelly WJ,
    2. Shah NJ,
    3. Subramaniam DS

    . Management of brain metastases in epidermal growth factor receptor mutant non-small-cell lung cancer. Front Oncol 2018;8:208–09 doi:10.3389/fonc.2018.00208 pmid:30018881

    CrossRefPubMed
57. 57.↵
    1. Shepard MJ,
    2. Xu Z,
    3. Donahue J, et al

    . Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non–small cell lung cancer to the brain: a matched cohort study. J Neurosurg 2019 Jul 26. [Epub ahead of print] doi:10.3171/2019.4.JNS19822 pmid:31349225

    CrossRefPubMed
58. 58.↵
    1. Chen L,
    2. Douglass J,
    3. Kleinberg L, et al

    . Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma. Int J Radiat Oncol Biol Phys 2018;100:916–25 doi:10.1016/j.ijrobp.2017.11.041 pmid:29485071

    CrossRefPubMed
59. 59.↵
    1. Narayanan V,
    2. Honce MJ,
    3. Mehrotra S, et al

    . Cystic brain metastases occurring in anaplastic lymphoma kinase gene rearranged non-small-cell lung cancer patients receiving crizotinib. Clin Lung Cancer 2016;17:85–90 doi:10.1016/j.cllc.2015.07.003 pmid:26314227

    CrossRefPubMed
60. 60.↵
    1. Essenmacher AC,
    2. Watal P,
    3. Bathla G, et al

    . Brain metastases from adenocarcinoma of the lung with truly cystic magnetic resonance imaging appearance. Clin Imaging 2018;52:203–07 doi:10.1016/j.clinimag.2018.07.023 pmid:30125846

    CrossRefPubMed
61. 61.↵
    1. Zee YK,
    2. Chin TM,
    3. Wong ASC

    . Fatal cystic change of brain metastasis after response to gefitinib in non-small-cell lung cancer. J Clin Oncol 2009;27:145–46 doi:10.1200/JCO.2009.22.4501 pmid:19667265

    CrossRefPubMed
62. 62.↵
    1. Schwartz LH,
    2. Litière S,
    3. de Vries E, et al

    . RECIST 1.1: update and clarification—from the RECIST Committee. Eur J Cancer 2016;62:132–37 doi:10.1016/j.ejca.2016.03.081 pmid:27189322

    CrossRefPubMed
63. 63.↵
    1. Lin NU,
    2. Lee EQ,
    3. Aoyama H, et al

    ; Response Assessment in Neuro-Oncology (RANO) group. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol 2015;16:e270–78 doi:10.1016/S1470-2045(15)70057-4 pmid:26065612

    CrossRefPubMed
64. 64.↵
    1. Chamberlain M,
    2. Junck L,
    3. Brandsma D, et al

    . Leptomeningeal metastases: a RANO proposal for response criteria. Neuro Oncol 2017;19:484–92 doi:10.1093/neuonc/now183 pmid:28039364

    CrossRefPubMed
65. 65.↵
    1. Lin CY,
    2. Chang CC,
    3. Su PL, et al

    . Brain MRI imaging characteristics predict treatment response and outcome in patients with de novo brain metastasis of EGFR-mutated NSCLC. Medicine (Baltimore) 2019;98:e16766 doi:10.1097/MD.0000000000016766 pmid:31415376

    CrossRefPubMed
66. 66.↵
    1. Minniti G,
    2. Clarke E,
    3. Lanzetta G, et al

    . Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol 2011;6:4 8 doi:10.1186/1748-717X-6-48 pmid:21575163

    CrossRefPubMed
67. 67.↵
    1. Kohutek ZA,
    2. Yamada Y,
    3. Chan TA, et al

    . Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases. J Neurooncol 2015;125:149–56 doi:10.1007/s11060-015-1881-3 pmid:26307446

    CrossRefPubMed
68. 68.↵
    1. Miller JA,
    2. Bennett EE,
    3. Xiao R, et al

    . Association between radiation necrosis and tumor biology after stereotactic radiosurgery for brain metastasis. Int J Radiat Oncol Biol Phys 2016;96:1060–69 doi:10.1016/j.ijrobp.2016.08.039 pmid:27742540

    CrossRefPubMed
69. 69.↵
    1. Gan GN,
    2. Weickhardt AJ,
    3. Scheier B, et al

    . Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. Int J Radiat Oncol Biol Phys 2014;88:892–98 doi:10.1016/j.ijrobp.2013.11.010 pmid:24462383

    CrossRefPubMed
70. 70.↵
    1. Ou SH,
    2. Weitz M,
    3. Jalas JR, et al

    . Alectinib induced CNS radiation necrosis in an ALK + NSCLC patient with a remote (7 years) history of brain radiation. Lung Cancer 2016;96:15–18 doi:10.1016/j.lungcan.2016.03.008 pmid:27133743

    CrossRefPubMed
71. 71.↵
    1. LeCompte MC,
    2. McTyre E,
    3. Henson

    A, et al. Survival and failure outcomes predicted by brain metastasis volumetric kinetics in melanoma patients following upfront treatment with stereotactic radiosurgery alone. Cureus 2017;9:e1934 doi:10.7759/cureus.1934 pmid:29464141

    CrossRefPubMed
72. 72.↵
    1. Kang TW,
    2. Kim ST,
    3. Byun HS, et al

    . Morphological and functional MRI, MRS, perfusion and diffusion changes after radiosurgery of brain metastasis. Eur J Radiol 2009;72:370–80 doi:10.1016/j.ejrad.2008.08.009 pmid:18829196

    CrossRefPubMed
73. 73.↵
    1. Jakubovic R,
    2. Zhou S,
    3. Heyn C, et al

    . The predictive capacity of apparent diffusion coefficient (ADC) in response assessment of brain metastases following radiation. Clin Exp Metastasis 2016;33:277–84 doi:10.1007/s10585-016-9778-x pmid:26786978

    CrossRefPubMed
74. 74.↵
    1. Abdulla DS,
    2. Scheffler M,
    3. Brandes V, et al

    . Monitoring treatment response to erlotinib in EGFR-mutated non–small-cell lung cancer brain metastases using serial O-(2- [18 F]fluoroethyl)-L-tyrosine PET. Clin Lung Cancer 2019;20:e148–51 doi:10.1016/j.cllc.2018.10.011 pmid:30528316

    CrossRefPubMed
75. 75.↵
    1. Essig M,
    2. Waschkies M,
    3. Wenz F, et al

    . Assessment of brain metastases with dynamic susceptibility-weighted contrast-enhanced MR imaging: initial results. Radiology 2003;228:193–99 doi:10.1148/radiol.2281020298 pmid:12832582

    CrossRefPubMed
76. 76.↵
    1. Mahmood F,
    2. Johannesen HH,
    3. Geertsen P, et al

    . Repeated diffusion MRI reveals earliest time point for stratification of radiotherapy response in brain metastases. Phys Med Biol 2017;62:2990–3002 doi:10.1088/1361-6560/aa5249 pmid:28306548

    CrossRefPubMed
77. 77.↵
    1. Huang CF,
    2. Chou HH,
    3. Tu HT, et al

    . Diffusion magnetic resonance imaging as an evaluation of the response of brain metastases treated by stereotactic radiosurgery. Surg Neurol 2008;69:62–68 doi:10.1016/j.surneu.2007.02.021 pmid:18054618

    CrossRefPubMed